Edition:
United Kingdom

Hill-Rom Holdings Inc (HRC.N)

HRC.N on New York Stock Exchange

92.76USD
7 Dec 2018
Change (% chg)

$-2.99 (-3.12%)
Prev Close
$95.75
Open
$95.32
Day's High
$95.82
Day's Low
$92.59
Volume
108,411
Avg. Vol
104,409
52-wk High
$99.55
52-wk Low
$78.19

Summary

Name Age Since Current Position

William Dempsey

66 2018 Executive Chairman of the Board

John Groetelaars

52 2018 President, Chief Executive Officer, Director

Barbara Bodem

50 2018 Chief Financial Officer, Senior Vice President

Kenneth Meyers

56 2015 Chief Human Resource Officer, Senior Vice President

Brian Lawrence

46 2017 Senior Vice President - Innovation and Connectivity and Chief Technology Officer

Sue-Jean Lin

2016 Senior Vice President, Chief Information Officer

Deborah Rasin

51 2016 Senior Vice President, Chief Legal Officer, Secretary

Mary Ladone

2018 Senior Vice President - Corporate Development, Strategy and Investor Relations

Andreas Frank

41 2018 Senior Vice President, President - Front Line Care Business

Paul Johnson

52 2016 Senior Vice President, President of Patient Support Systems

Timothy Lawrence

54 2017 Senior Vice President - Operations

Carlos Marum

58 2015 Senior Vice President, President - Hill-Rom International

Kevin McCulloch

2017 Senior Vice President and President, Global Solutions

Michael Murphy

52 2012 Senior Vice President - Quality Assurance and Regulatory Affairs

Francisco Vega

56 2017 Senior Vice President - President, Surgical Solutions

Ilana Shulman

2014 Chief Compliance Officer

Richard Wagner

50 2018 Vice President, Corporate Controller

Ronald Malone

63 2018 Lead Independent Director

Mary Garrett

59 2017 Director

Nancy Schlichting

63 2017 Director

Gary Ellis

61 2017 Independent Director

James Giertz

61 2009 Independent Director

Charles Golden

71 2002 Independent Director

William Kucheman

68 2013 Independent Director

Stacy Seng

53 2014 Independent Director

Biographies

Name Description

William Dempsey

Mr. William G. Dempsey is Executive Chairman of the Board of the Company, effective March 7, 2018. Mr. Dempsey has served as a director of Hill-Rom since 2014. Mr. Dempsey previously held various executive positions with Abbott Laboratories from 1982 until 2007, including Executive Vice President of Global Pharmaceuticals from 2006, Senior Vice President of Pharmaceutical Operations from 2003 and Senior Vice President of International Operations from 1999. He currently serves as a director of Ashland, Inc. (where he serves on the audit, governance and nominating, environmental, health and safety, and quality committees), and was previously on the boards of MDS, Inc. through 2011, Nordion, Inc. through 2014, Hospira, Inc., through 2015 and Landauer Inc., through 2017. He has previously served as a member of the Salvation Army Advisory Board in Chicago, as Chairman of the International Section of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as Chairman of the Accelerating Access Initiative (a cooperative public-private partnership of UNAIDS, the World Bank, and six research-based pharmaceutical companies). He is a member of the Board of Trustees for the Guadalupe Center in Immokalee, Florida. Mr. Dempsey has extensive experience in the health care industry, including positions in management and on the boards of several companies. In addition, his international operations experience and his service as a senior officer at a large company makes him highly qualified to serve on the Board.

John Groetelaars

Mr. John P. Groetelaars has been appointed as President, Chief Executive Officer, Director of the company effective May 14, 2018. John Groetelaarsmost recently served as executive vice president and president of the Interventional Segment at Becton, Dickinson and Company (BD). In this role, Mr. Groetelaars' responsibilities included the global strategic, operational and commercial performance of the Interventional Segment, as well as accountability for delivering the segment's global financial performance and innovation platform. Prior to that, Mr. Groetelaars held roles of increasing responsibility at C.R. Bard. Mr. Groetelaars joined C.R. Bard in 2008 as vice president and general manager, Davol Inc., and was appointed president of Davol in 2009. In 2013, Mr. Groetelaars was promoted to group vice president and in 2015 he was promoted to group president, a position he held until C.R. Bard was acquired by BD inDecember 2017. Prior to joining C.R. Bard, Mr. Groetelaars held various international leadership positions at Boston Scientific Corporation from 2001 until joining C.R. Bard. Prior to Boston Scientific, Mr. Groetelaars held positions in general management, marketing, business development and sales with Guidant Corporation and with Eli Lilly. John received a bachelor's degree in Mechanical Engineering from Kettering University in Michigan, and an MBA from Columbia University in New York.

Barbara Bodem

Ms. Barbara W. Bodem is appointed as Chief Financial Officer, Senior Vice President of the Company effective December 3, 2018. Ms. Bodem joins Hill-Rom from Mallinckrodt, where she served as senior vice president, Finance, for the past three years. Earlier in her career Ms. Bodem worked at Hospira as vice president, Global Commercial Finance, as well as at Eli Lilly and Company, where she held a variety of Finance roles in the U.S. and the U.K., including serving as CFO for Lilly Oncology. Ms. Bodem recently served as a member of the board of directors of Invacare Corporation.She earned her bachelor's of science in finance and MBA fromIndiana University.

Kenneth Meyers

Mr. Kenneth F. Meyers is a Chief Human Resource Officer, Senior Vice President of the Company. Prior to joining Hill-Rom, Mr. Meyers held the same role at Hospira, Inc. from 2008 until its acquisition in 2015 by Pfizer, Inc. For several years prior to his tenure at Hospira, Mr. Meyers was a partner at Mercer / Oliver Wyman Consulting, specializing in leadership development of general managers and HR professionals. Prior to Mercer / Oliver Wyman, Mr. Meyers served as senior vice president, Human Resources, for Starbucks Coffee International. Mr. Meyers also held human resources positions of increasing responsibility during his career at The Gymboree Corporation, Walt Disney Imagineering and United Technologies. He has lived and worked in the U.S., England, France and South Africa. Mr. Meyers serves on the board of directors of INC Research (NASDAQ: INCR), a global Contract Research Organization providing clinical development services to the pharmaceutical industry, where he chairs the Compensation Committee and serves on the Nominating & Governance Committee. Mr. Meyers holds a bachelor’s degree in International Business and Human Resource Management from the University of Pennsylvania’s Wharton School and an MBA from the Harvard Business School.

Brian Lawrence

Mr. Brian D. Lawrence is Senior Vice President - Innovation and Connectivity and Chief Technology Officer of Hill-Rom Holdings, Inc since October 2017. Mr. Lawrence joined Hill-Rom in December 2010 as senior vice president and chief technology officer. Prior to Hill-Rom, he served as chief technology officer for GE Healthcare’s Life Support Solutions business and held other leadership and innovation positions in GE's Global Research Center. Before GE, Mr. Lawrence was president and CEO of Extend Optical Systems Corporation and senior vice president of Research and Development and chief technology officer for Molecular OptoElectronics Corporation. Mr. Lawrence holds undergraduate and graduate degrees from the Massachusetts Institute of Technology (MIT) and a Ph.D. from the Center for Research and Education in Optics and Lasers (CREOL) at the University of Central Florida.

Sue-Jean Lin

Ms. Sue-Jean Lin is the Senior Vice President and Chief Information Officer of the company. Prior to joining Hill-Rom, Ms. Lin was most recently senior vice president and chief information officer for Allergan, a Fortune 500 multi-specialty pharmaceutical and consumer medical device company with business operations in more than 100 countries. She also held the role of vice president of Finance & EMEA Regional Controller based in the U.K. for seven years. She serves on the non-profit board of Wise & Healthy Aging, an organization that provides services and programs to enhance healthy aging, and on the executive advisory board of Women in Technology International (WITI). Ms. Lin holds a bachelor’s degree in accounting and an MBA from the University of Nevada, Reno, is a Certified Management Accountant and has completed the Executive Leadership Program from the University of Southern California, Marshall School of Business; the Director’s College program at Stanford Law School.

Deborah Rasin

Ms. Deborah Rasin is Senior Vice President, Chief Legal Officer and Secretary of the Company. Previously she was General Counsel for Dentsply Sirona, Inc. Prior to Dentsply, Ms. Rasin served as General Counsel at Samsonite Corporation (for which she worked in Denver and London) and as a senior attorney at GM (in Detroit and Zurich).

Mary Ladone

Ms. Mary Kay Ladone is Senior Vice President - Corporate Development, Strategy and Investor Relations of the Company. Ms. Ladone has served as vice president, Investor Relations, since joining Hill-Rom inJuly 2016. Previously, she served as senior vice president, Investor Relations, of Baxalta Incorporated. Prior to that, she served in a variety of finance, business development and investor relations roles for Baxter International. Ms. Ladone has been recognized for her expertise with numerous honors and awards in the field of Investor Relations by both her peers and Wall Street, including national recognition by Institutional Investor Magazine . Ms. Ladone holds a degree in finance and economics from the University of Notre Dame, and is a member of the Edward Elmhurst Hospital System Board of Trustees.

Andreas Frank

Mr. Andreas G. Frank is re-designated as Senior Vice President, President - Front Line Care Business of the Company. was Senior Vice President - Corporate Development and Strategy, and Chief Transformation Officer of the Company. Before joining Hill-Rom, Mr. Frank was Director, Corporate Development at Danaher Corporation. Previously, he worked in the Corporate Finance and Strategy practice at the consulting firm McKinsey & Company.

Paul Johnson

Mr. Paul Johnson is Senior Vice President, President of Patient Support Systems of the Company. He had previously served as president, PSS North America. Before joining Hill-Rom in 2013, Mr. Johnson held various commercial leadership positions at Life Technologies and GE Healthcare.

Timothy Lawrence

Mr. Timothy P. Lawrence is the Senior Vice President - Operations of the Company since September 2017. Prior to joining Hill-Rom, Mr. Lawrence spent 15 years in various positions with increasing responsibility at Baxter International Inc., including most recently as corporate vice president for Operations where he oversaw 60 manufacturing plants spanning 30 countries. Earlier in his career, he served as a general manager for Precision Components International, part of The Wertheimer Group, and for Pratt and Whitney. Prior to his business career, Mr. Lawrence was a commissioned infantry officer in the U.S. Army. He holds a bachelor's degree from the United States Military Academy at West Point and a master's degree in management from Purdue University.

Carlos Marum

Mr. Carlos Marum Alonso is Senior Vice President, President - Hill-Rom International of the Company. Before joining Hill-Rom, Mr. Alonso served as the President and CEO of the Esaote Group, a medical imaging leader based in Genova, Italy. Prior to the Esaote Group, Mr. Alonso served as the CEO of Esteve Pharmaceuticals based in Barcelona, Spain, and held various leadership roles of increasing responsibility with Baxter International, Inc. over the course of fifteen years, including serving as Global President of the Renal Division.

Kevin McCulloch

Mr. Kevin McCulloch is the Senior Vice President and President, Global Solutions of the Company since May 2017. Prior to joining Hill-Rom, Mr. McCulloch served as chief business officer for Water Street Healthcare Partners Pharmaceutical Holdings. Before that, Mr. McCulloch spent 15 years with Baxter, where he served as general manager and/or president of several different businesses, including Global Services, Fenwal and Global Fluid Systems. He spent the earlier part of his career in senior sales and marketing roles at GD Searle and The Upjohn Company (both now part of Pfizer). Mr. McCulloch holds a bachelor’s degree in biology from the University of Michigan and an MBA from Northwestern University’s Kellogg Graduate of School of Management.

Michael Murphy

Mr. Michael J. Murphy is Senior Vice President - Quality Assurance, Regulatory Affairs of Hill-Rom Holdings, Inc since July 2012. Mr. Murphy joined Hill-Rom as vice president of QARA in May 2011. Prior to joining Hill-Rom, he was with Baxter International Inc., where he spent three years in Switzerland as vice president of Quality for Europe, Middle East, & Africa before being promoted to vice president II, Corporate Quality at Baxter headquarters outside Chicago. Mr. Murphy’s previous experience also included senior-level Quality & Regulatory positions at Boston Scientific and a company formerly owned by J&J, Harmac Medical. Mr. Murphy served in the U.S. Air Force active duty and reserve and holds a bachelor’s degree in Industrial Technology Management with concentrations in Biomedical Engineering and Management from The State University of New York, Buffalo.

Francisco Vega

Mr. Francisco Canal Vega is Senior Vice President - President, Surgical Solutions of the Company. He had served as President of our Europe region. Before joining Hill-Rom, Mr. Canal held several senior executive roles at Baxter, Gambro, and Smith & Nephew.

Ilana Shulman

Ms. Ilana Shulman is the Chief Compliance Officer of the company. Prior to joining Hill-Rom, Ms. Shulman worked at Astellas U.S., where she was responsible for all legal and compliance issues for Latin America as well as the anti-bribery and anti-corruption program. Prior to Astellas U.S., she spent 12 years at Pfizer in a variety of roles in Legal, Compliance and Public Affairs, including supporting the Worldwide Public Affairs and Policy groups and the Latin American, European and Japan/Asia regions. Before joining Pfizer, Ms. Shulman worked at Sullivan & Cromwell, where she specialized in securities transactions with Latin American and Spanish clients. Ms. Shulman also clerked for Chief Judge Gregory Carman on the U.S. Court of International Trade. Ms. Shulman holds a bachelor’s degree in Government and Spanish from Dartmouth College, a juris doctor from Columbia Law School and a master’s degree in International Affairs from Columbia School of International and Public Affairs.

Richard Wagner

Mr. Richard M. Wagner is Vice President, Corporate Controller of the Company. Before joining Hill-Rom, Mr. Wagner was Vice President, Finance at Cree, Incorporated and prior to that role, he served as Vice President, Corporate Controller at Dentsply Sirona Incorporated.

Ronald Malone

Mr. Ronald A. Malone is Lead Independent Director of the Company, effective March 7, 2018 . Mr. Malone has served as a director of Hill-Rom since 2007. He served as Chairman of the Board of Gentiva Health Services from 2002 to 2011, as Chief Executive Officer from 2002 through 2008, and as a director through 2012. He joined Gentiva in 2000 as Executive Vice President and President of Gentiva’s Home Health Division. Prior to joining Gentiva, he served in various positions with Olsten Corporation including Executive Vice President of Olsten Corporation and President, Olsten Staffing Services, United States and Canada. He is a director of Capital Senior Living, Inc., a former director of the National Association for Home Care & Hospice and a former director and chairman of the Alliance for Home Health Quality and Innovation. Mr. Malone has an intimate knowledge of the home health industry and expertise in the legislative and regulatory landscape affecting healthcare companies. In addition, his experience as an officer of other health care companies provides the Board with valuable operational experience.

Mary Garrett

Ms. Mary Garrett is a Director of the Company. Ms. Garrett most recently led Global Marketing for IBM Corporation, a leading global provider of technology products and services, from 2008 until her retirement in December 2015. She joined IBM in 1981 as an electrical engineer and went on to serve in a number of senior roles including: Partnership Executive for Memorial Sloan Kettering, Vice President, Small and Medium Business for Global Technology Services, Vice President of Marketing for Global Technology Services, and Vice President of Marketing for eBusiness Hosting. Ms. Garrett currently serves as a board member and on the audit committee for Ethan Allen Interiors, Inc. She is an active mentor in W.O.M.E.N. in America, a professional development group aimed at advancing promising professional women, and is also on the board of the American Marketing Association, serving as Chair. Ms. Garrett serves on the technology and strategy committees of the Western Connecticut Health Network. Ms. Garrett has extensive experience in the technology industry, including digital transformation, big data and cognitive analytics, cybersecurity, and cloud computing. In addition, her broad international background, marketing expertise, and business leadership experience, as well as experience as a public company director make her highly qualified to serve on the Board.

Nancy Schlichting

Ms. Nancy M. Schlichting is Director of the Company. Ms. Schlichting is the retired President and Chief Executive officer of Henry Ford Health System (“HFHS”) in Detroit, Michigan, serving in this role from June, 2003 to January, 2017. She joined HFHS in 1998 as Senior Vice President and Chief Administrative Officer, and was promoted to Executive Vice President and Chief Operating Officer from 1999 to 2003, and President and Chief Executive Officer of Henry Ford Hospital from 2001 to 2003. She currently serves as a director of Walgreens Boots Alliance (12 years of Board service, chair of Compensation Committee and member of Audit Committee), a director on the board of directors of HealthSouth Corporation (member of Compliance and Quality of Care Committee), a member of the Board of Managers of Ardent Health Services, and a trustee of Kresge Foundation (chair of Compensation Committee and member of Audit Committee), Duke University Health System, and the Detroit Symphony Orchestra. Ms. Schlichting's career in healthcare administration spans more than 35 years in senior-level executive roles. She is credited with leading HFHS through a dramatic financial turnaround, and for award-winning customer service, quality and diversity initiatives, including HFHS being the recipient of the 2011 Malcolm Baldrige National Quality Award. Her significant healthcare leadership background, and her comprehensive knowledge of finance and accounting gained by education, experience and service on audit committees for more than a decade provide the Board with additional depth and invaluable insights.

Gary Ellis

Mr. Gary L. Ellis is an Independent Director of the Company. He was previously Chief Financial Officer and Senior Vice President of Medtronic plc. Mr. Ellis also serves as an independent director of The Toro Company. He is a Certified Public Accountant. Mr. Ellis brings significant financial leadership experience and expertise to the Board and provides oversight regarding capital structure, financial condition and policies, long-range financial objectives, financing requirements and arrangements, capital budgets and expenditures, risk-management, and strategic planning matters. Additionally, Mr. Ellis contributes his international experience managing worldwide financial operations and analyzing financial implications of merger and acquisition transactions, as well as aligning business strategies and financial decisions.

James Giertz

Mr. James R. Giertz is an Independent Director of the Company. Mr. Giertz has served as a director of Hill-Rom since 2009. He served as the Senior Vice President and Chief Financial Officer of H.B. Fuller Company, St. Paul, Minnesota, until his retirement. Prior to joining H.B. Fuller, he served as Senior Managing Director, Chief Financial Officer and, for several months in 2007 a director, of Residential Capital, LLC, one of the largest originators, servicers and securitizers of home loans in the United States. Prior to that, he was Senior Vice President of the Industrial Products division, and Chief Financial Officer of Donaldson Company, Inc., a worldwide provider of filtration systems and replacement parts. In addition, Mr. Giertz served as assistant treasurer of the parent company at General Motors, and also held several international treasury positions in Canada and Europe. Mr. Giertz currently serves as a director of Schneider National, Inc. and Junior Achievement of the Upper Midwest and is also a member of the Board of Regents of Concordia University of St. Paul. Mr. Giertz has extensive experience in financial statement preparation and accounting, and operations, and his service as a senior officer in large corporations brings knowledge and valuable insight to the Board. In addition, his international experience is a valuable asset to the Board.

Charles Golden

Mr. Charles E. Golden is an Independent Director of the Company. Mr. Golden has served as director of Hill-Rom since 2002. He served as Executive Vice President and Chief Financial Officer and a director of Eli Lilly and Company, an international developer, manufacturer and seller of pharmaceutical products, from 1996 until his retirement in 2006. Prior to joining Eli Lilly, he held a number of positions with General Motors Corporation since 1970, including Corporate Vice President, Chairman and Managing Director of the Vauxhall Motors subsidiary and Corporate Treasurer. He is currently on the board of Eaton Corporation PLC, and was formerly on the boards of Unilever NV/PLC through 2014. He also serves as a director of the Lilly Endowment. Mr. Golden has a comprehensive knowledge of both U.S. GAAP and IFRS, has extensive experience in financial statement preparation, accounting, corporate finance, risk management and investor relations both in the U.S. and Europe. His significant financial healthcare experience brings valuable financial and operations rigor and insight to the Board.

William Kucheman

Mr. William H. Kucheman is an Independent Director of the Company. Mr. Kucheman has served as a director of Hill-Rom since 2013. He previously served as interim Chief Executive Officer for Boston Scientific Corp. Before being named interim CEO in October 2011, he was Executive Vice President and President of the Cardiology, Rhythm and Vascular (CRV) Group of Boston Scientific. He joined the company in 1995 as a result of Boston Scientific’s acquisition of SCIMED Life Systems, Inc., becoming Senior Vice President of Marketing. In this role, Mr. Kucheman was responsible for global marketing. He has served on several industry boards, including the board of directors of the Global Health Exchange and on the boards of several non-public companies. Mr. Kucheman’s executive experience with invasive medical devices, including FDA regulation, commercialization process, government reimbursement, and clinical marketing, makes him highly qualified to serve on the Board.

Stacy Seng

Ms. Stacy Enxing Seng is an Independent Director of the Company, Ms. Enxing Seng has served as director of Hill-Rom since 2015. She is the former President, Vascular Therapies of Covidien from 2011 to 2014 and prior to that was President of Peripheral Vascular of Covidien from 2010 to 2011. Ms. Enxing Seng joined Covidien in 2010 through the $2.6B acquisition of ev3 Incorporated, where she was a founding member and executive officer responsible for leading their Peripheral Vascular division from 2001 to 2010. Prior to that, she held positions of increasing responsibility with SCIMED, Boston Scientific, American Hospital Supply and Baxter. Ms. Enxing Seng currently is a Venture Partner with Lightstone Venture Capital and serves on the boards of Sonova Holding AG and Solace Therapeutics, and was formerly on the boards of Spirox, Inc., FIRE 1 Medical Incubator and CV Ingenuity. Ms. Enxing Seng has broad experience as a former senior executive responsible for a world-wide business unit of a major medical device company. In addition, she has significant experience as a co-founder of a successful medical device start-up. Her operational experience at a large medical device company, combined with her broad scope experience gained from her role as a co-founder of a medical device company, provide the Board with valuable insights across marketing, sales, innovation and a variety of other medical device related areas.